vi-0521
Pediatric Obesity
VIVUS LLCPhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
575 Active assets in the Pediatric Obesity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
vi-0521 VIVUS LLC | Phase 4 | BBB |
Efsubaglutide Alfa The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 4 | BBB |
Phentermine Russell McCulloh, MD | Phase 4 | BBB |
asc30 Ascletis Pharma (China) Co., Limited | Phase 2 | BBB |
Tirzepatide LABORATORIOS INDUFAR | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
vi-0521 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →